Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.730
-0.040 (-2.26%)
Jul 11, 2025, 4:00 PM - Market closed
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
51.13M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GANX News
- 13 days ago - Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - GlobeNewsWire
- 2 months ago - Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 2 months ago - Gain Therapeutics to Participate at The Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - GlobeNewsWire
- 3 months ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire